ClinicalTrials.gg
Active, not recruitingNCT05955508Updated Apr 13, 2026

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

A Phase 2 interventional study of Linvoseltamab in Smoldering Multiple Myeloma (SMM), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM).

The aim of the study is to understand the safety and tolerability (how the body reacts to linvoseltamab) as well as the effectiveness (how well linvoseltamab eliminates plasma cells and prevents the development of MM) of the study drug. There are 2 parts to the study.

  • In Part 1, linvoseltamab will be given to a small number of participants to study the early side effects (safety) of the study drug and make sure the treatment is acceptable.
  • In Part 2, linvoseltamab will be given to more participants to further assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat HR-SMM and prevent progression to MM.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab (study drug) have improvement of their HR-SMM?
  • What side effects may happen from taking the study drug?
  • How much study drug is in the blood at different times?
  • Whether the body makes antibodies against the study drug (which could make linvoseltamab less effective or could lead to side effects)
02

Conditions studied

  • Smoldering Multiple Myeloma (SMM)

Keywords

  • Linvoseltamab
  • Multiple Myeloma (MM)
  • B cell Maturation Antigen (BCMA)
  • Bispecific antibody
03

In context

Smoldering Multiple Myeloma

101 studies on the registry are indexed under Smoldering Multiple Myeloma; 34 are open to participants now.

This study's enrollment of 40 is above the median of 31 across 71 interventional studies indexed under Smoldering Multiple Myeloma.

Browse Smoldering Multiple Myeloma studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. High-risk SMM diagnosis within 5 years of study enrollment, as described in the protocol
  2. (ECOG) performance status ≤1
  3. Adequate hematologic and hepatic function, as described in the protocol
  4. Estimated ≥30 mL/min/1.73 m\^2

Key Exclusion Criteria:

  1. Evidence of myeloma defining events *SLiM CRAB, as described in the protocol

    *SLiM (greater than or equal to Sixty percent clonal plasma cells in the bone marrow, involved/uninvolved free Light chain ratio of ≥100 with the involved free light chain (FLC) being ≥100 mg/L, MRI with >1 focal lesion) CRAB (hyperCalcemia, Renal insufficiency, Anemia, or lytic Bone lesions)

  2. Diagnosis of systemic light chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), soft tissue plasmacytoma, or symptomatic multiple myeloma
  3. cardiac or vascular disease within 3 months of study enrollment, as described in the protocol
  4. Any infection requiring hospitalization or treatment with intravenous anti-infectives within 28 days of first dose of study drug
  5. Uncontrolled (HIV), Virus (HBV), or Virus (HCV) infection; or other uncontrolled infection or unexplained signs of infection, as described in the protocol
  6. History of severe allergic reaction attributed to compounds with a similar chemical or biologic composition as the study drug or

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Safety Run-In (Part 1)

    Drug: Linvoseltamab

  • Experimental
    Expansion (Part 2)

    Drug: Linvoseltamab

Interventions

  • Administered per the protocol

    Also known as: REGN5458, Lynozyfic™

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events of Special Interest (AESI) during the safety run-in observation period

    AESI include grade 2 or higher Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    Time frame: Up to 35 days

  2. Frequency of Treatment-Emergent Adverse Events (TEAEs) during the safety run-in observation period

    Time frame: Up to 35 days

  3. Severity of TEAEs during the safety run-in observation period

    Time frame: Up to 35 days

  4. Complete Response (CR) as determined by the investigator

    Time frame: Up to 7 years

  5. Minimal Residual Disease (MRD) negativity

    Time frame: At 12 months

  6. MRD negativity

    Time frame: At 24 months

Secondary outcomes

  1. Frequency of TEAEs during expansion part

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 7 years

  2. Severity of TEAEs during expansion part

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 7 years

  3. Frequency of Serious Adverse Events (SAEs)

    Time frame: Up to 7 years

  4. Severity of SAEs

    Time frame: Up to 7 years

  5. Frequency of laboratory abnormalities

    Time frame: Up to 7 years

  6. Severity of laboratory abnormalities

    Time frame: Up to 7 years

  7. Overall response of Partial Response (PR) or better

    Time frame: Up to 7 years

  8. Duration Of Response (DOR)

    Time frame: Up to 7 years

  9. Biochemical Progression-Free-Survival (PFS)

    Time frame: Up to 7 years

  10. MRD negativity among participants that achieve Very Good Partial Response (VGPR) or better

    Time frame: Up to 3 years after end of treatment

  11. Sustained MRD negativity

    Time frame: Up to 3 years after end of treatment

  12. Time from treatment initiation to date of any myeloma-defining event

    Time frame: Up to 7 years

  13. Time from start of treatment to date of progression to MM or death

    Time frame: Up to 7 years

  14. Time to initiation of first-line treatment for MM

    Time frame: Up to 7 years

  15. Overall Survival (OS)

    Time frame: Up to 7 years

  16. Concentration of linvoseltamab in serum

    Time frame: Up to 2 years

  17. Incidence of Anti-Drug Antibodies (ADAs) to linvoseltamab

    Time frame: Up to 2 years

  18. Magnitude of ADAs to linvoseltamab

    Time frame: Up to 2 years

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2033, 107 months after the start.

Of 26 phase 2 interventional studies under Smoldering Multiple Myeloma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 107 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 21, 2023
StartActual
Jan 30, 2024
Primary completionEst.
Jan 25, 2033
CompletionEst.
Jan 25, 2033
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05955508
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Jan 30, 2024
Primary completion
Jan 25, 2033 (estimated)
Completion
Jan 25, 2033 (estimated)
Last update
Apr 13, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion